Abstract:BACKGROUND Most patients with hepatocellular carcinoma (HCC) have lost the opportunity for direct surgery at the time of diagnosis. Transarterial chemoembolization (TACE) combined with immune checkpoint inhibitors or tyrosine kinase inhibitors (TKI) can partially transform some unresectable HCC and improve the prognosis effectively. However, based on the promising prospects of combined targeted and immunotherapy for the effective treatment of HCC, the positive role of palliative surgery in the conversion treatment of advanced HCC urgently needs further intensive re-assessment. CASE SUMMARY In this study, we describe two successful cases of "conversion therapy for unresectable HCC" achieved mainly by palliative surgery combined with TACE plus immunotherapy and TKIs. A 48-year-old patient with newly diagnosed HCC, presenting with a 6-cm mass in the segment VII/VIII of the right liver with multiple intrahepatic metastases, could not undergo one-stage radical surgical resection. He underwent palliative surgery with radiofrequency of metastatic lesions and the palliative resection of the primary mass, and received subsequent TACE treatments twice in the early postoperative period (2 weeks and 6 weeks), in addition to targeted and immune combination therapy with sintilimab injection and oral lenvatinib. No evidence of recurrence was observed during the 11-month follow-up period after surgery. The other patient was a 47-year-old patient with massive HCC (18 cm × 15 cm × 4.5 cm) in the left liver with severe cirrhosis. The left portal branch was occluded and a tumor thrombus formed, and the tumor partly involved the middle hepatic vein. The patient underwent palliative surgery of left hemihepatectomy (including resection of the middle hepatic vein) for HCC, followed by three TACE procedures and oral TKIs 2 weeks after surgery. Six months later, the re-examination via computed tomography revealed no tumour activity in the remaining right liver, while magnetic resonance imaging revealed slight local tumor enhancement in the caudate lobe of the liver considered, TACE was performed once again, and during the next follow-up of 10 months did not reveal new intrahepatic lesions or distant metastases. CONCLUSION These cases demonstrate that the addition of palliative surgery to conversion therapy in a selected population with a high tumor burden could benefit patients with initially unresectable HCC.

Surgical Resection of Pancreatic Hepatoid Carcinoma Followed by Combined Transarterial Chemoembolization and Immunotherapy: A Case Report

Hepatocellular Carcinoma Complicated with Huge Posterior Pancreas Head Lymph Node Metastasis and Primary Renal Carcinoma: A Case Report

Systematic sequential therapy for <i>ex vivo</i> liver resection and autotransplantation: A case report and review of literature

Multidisciplinary Treatment with Chemotherapy, Targeted Drug, and High-Intensity Focused Ultrasound in Advanced Pancreatic Carcinoma

Combined Pancreatoduodenectomy and Orthotopic Liver Transplantation for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Case Report

Case Report: Antiangiogenic Therapy Plus Immune Checkpoint Inhibitors Combined With Intratumoral Cryoablation for Hepatocellular Carcinoma

Case Report: A case of hepatocellular carcinoma with aberrant right hepatic artery treated with transarterial chemoembolization and infusion chemotherapy separately to bilobar lesion combining with systemic therapies and sequential hepatectomy

Case report and literature analysis: pancreatic hepatoid carcinoma with multiple lymph node metastases progressing to liver metastasis after pancreaticoduodenectomy

Neoadjuvant modified-FOLFIRINOX followed by surgical resection of both the primary and metastatic tumors of a pancreatic hepatoid carcinoma with synchronous liver metastasis: A case report.

Case Report: Transarterial Chemoembolization in Combination with Tislelizumab Downstages Unresectable Hepatocellular Carcinoma Followed by Radical Salvage Resection.

Transarterial Chemoembolization in Combination with Programmed Death-1/Programmed Cell Death-Ligand 1 Immunotherapy for Hepatocellular Carcinoma: A Mini Review

PD-1 combined with lenvatinib and TACE for the transformational treatment of hepatocellular carcinoma combined with portal vein tumor thrombus: a case report and literature review

The Resection of Hepatocellular Carcinoma in Caudate Lobe with Metastasis of Lymph Node: Case Report

Hepatic arterial infusion chemotherapy with implantable arterial access port for advanced-stage hepatocellular carcinoma: a case report

Successful Treatment Of A Case With Pancreatic Neuroendocrine Carcinoma With Focal Hepatoid Differentiation: A Case Report And Literature Review

Pathologically successful conversion hepatectomy for advanced giant hepatocellular carcinoma after multidisciplinary therapy: A case report and review of literature

Transarterial chemoembolization combined with atezolizumab plus bevacizumab conversion therapy for intermediate-stage hepatocellular carcinoma: a case report and literature review

Reassessment of Palliative Surgery in Conversion Therapy of Previously Unresectable Hepatocellular Carcinoma: Two Case Reports and Review of Literature

Hepatic Artery Infusion Chemotherapy Sequential Hepatic Artery Embolization Combined with Operation in the Treatment of Recurrent Massive Hepatocellular Carcinoma Achieved Pathological Complete Response: A Case Report

Combining PD-1 Inhibitor with VEGF/VEGFR2 Inhibitor in Chemothera-py: Report of a Patient with End-Stage Cholangiocarcinoma and Review of Literature